Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MG 1111

Next Previous
Drug Profile

MG 1111

Alternative Names: BARYCELA; MG-1111; MG-1111C

Latest Information Update: 21 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer GC Biopharma
  • Class Varicella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Varicella zoster virus infections

Most Recent Events

  • 17 Jul 2025 Registered for Varicella zoster virus infections (In children, Prevention) in Vietnam (SC)
  • 11 Jul 2025 GC Biopharma plans a phase III clinical trial for Varicella-zoster-virus-infections (In infants, In children, Prevention) in March 2026 (Injection) (NCT07054099)
  • 19 Feb 2023 GC Biopharma plans to commercialize BARYCELA in global markets

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top